DrugPatentWatch Database Preview

Details for Patent: 7,906,542

« Back to Dashboard

Which drugs does patent 7,906,542 protect, and when does it expire?

Patent 7,906,542 protects XIFAXAN and is included in two NDAs.

This patent has eighty-one patent family members in thirty-five countries.

Summary for Patent: 7,906,542

Title:	Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin
Abstract:	Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
Inventor(s):	Viscomi; Giuseppe Claudio (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT)
Assignee:	Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:	12/119,622
Patent Claim Types: see list of patent claims	Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,906,542

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes			Y	Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	022554-001	Mar 24, 2010		RX	Yes	Yes			Y	Y

Non-Orange Book US Patents Family Members for Patent 7,906,542

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,902,206	Polymorphic forms .alpha., .beta. and .gamma. of rifaximin
7,915,275	Use of polymorphic forms of rifaximin for medical preparations
7,923,553	Processes for the production of polymorphic forms of rifaximin
7,045,620	Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations

International Patents Family Members for US Patent 7,906,542

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	043547
Argentina	081991
Argentina	081992
Austria	361927